牛牛AI助理已提取核心訊息
Arcutis Biotherapeutics, Inc., a company listed in the United States, has received a Notice of Effectiveness from the Securities and Exchange Commission (SEC) on February 8, 2024. The notice indicates that the company's Form S-3 filing, associated with File Number 333-276794, is now effective as of 4:00 P.M. on the stated date. This development is a significant step for Arcutis Biotherapeutics, as it pertains to the company's registration statement under the SEC regulations.
Arcutis Biotherapeutics, Inc., a company listed in the United States, has received a Notice of Effectiveness from the Securities and Exchange Commission (SEC) on February 8, 2024. The notice indicates that the company's Form S-3 filing, associated with File Number 333-276794, is now effective as of 4:00 P.M. on the stated date. This development is a significant step for Arcutis Biotherapeutics, as it pertains to the company's registration statement under the SEC regulations.
在美國上市的公司Arcutis Biotherapeutics, Inc. 已於2024年2月8日收到美國證券交易委員會（SEC）的生效通知。該通知指出，該公司提交的與文件編號333-276794相關的S-3表格現已於規定日期下午4點生效。這一發展是Arcutis Biotherapeutics邁出的重要一步，因爲它與該公司根據美國證券交易委員會法規發佈的註冊聲明有關。
在美國上市的公司Arcutis Biotherapeutics, Inc. 已於2024年2月8日收到美國證券交易委員會（SEC）的生效通知。該通知指出，該公司提交的與文件編號333-276794相關的S-3表格現已於規定日期下午4點生效。這一發展是Arcutis Biotherapeutics邁出的重要一步，因爲它與該公司根據美國證券交易委員會法規發佈的註冊聲明有關。
有用
沒用